UK Data Support Immunoglobulin-Free Maintenance After Liver Transplant

Refining Prophylaxis in Post-Transplant Hepatitis B Management

The management of patients undergoing liver transplantation for hepatitis B virus-related end-stage liver disease has historically relied on a combination of hepatitis B immunoglobulin and nucleos(t)ide analogues (synthetic molecules that inhibit viral DNA synthesis) to prevent graft reinfection. While this dual approach significantly reduced recurrence rates compared to early monotherapy trials (Relative Risk 0.28; 95% CI 0.12 to 0.66), the necessity of lifelong immunoglobulin administration remains a subject of intense clinical debate [1, 2]. The introduction of high-potency antiviral agents with high genetic barriers to resistance (drugs that require multiple viral mutations to lose efficacy), such as entecavir and tenofovir, has led some centers to question the added value of immunoglobulin beyond the immediate perioperative period [3, 4]. Recent meta-analytic data involving 9,435 patients demonstrate that high-potency nucleos(t)ide analogue monotherapy achieves similar 10-year overall survival rates (81.2%) compared to combination therapy (86.4%) with a hazard ratio of 1.09 (95% CI 0.70 to 1.69) [3]. Furthermore, the lack of standardized protocols has resulted in significant international variation in how these biological agents are dosed and for how long they are maintained [5, 6]. As clinicians seek to balance efficacy with cost-effectiveness and patient convenience, the role of immunoglobulin-free maintenance regimens is under increasing scrutiny.

Heterogeneity in UK Prophylaxis Protocols

The researchers conducted a retrospective review of all liver transplantations related to the hepatitis B virus performed in the United Kingdom between 2010 and 2023. This study population included 273 patients, providing a comprehensive look at long-term management trends over a 13-year period. Within this cohort, the majority of individuals were at a high clinical threshold for viral relapse, as 81.7% of the patients were classified as high risk for hepatitis B virus recurrence. Despite this high-risk profile, the data revealed a lack of standardized application in preventive measures across the various transplant centers. Clinical practice patterns showed a heavy reliance on immunoglobulin therapy that did not always align with individual patient risk assessments. Specifically, 85% of patients received hepatitis B immunoglobulin during the post-transplant period regardless of their specific risk for recurrence. The researchers observed significant variation in hepatitis B immunoglobulin protocols among the different liver transplant centers in the United Kingdom, suggesting that local institutional preferences often dictate prophylaxis rather than a unified national standard. The duration of treatment also varied widely among the study participants. While some centers utilized short courses, 54.6% of patients continued hepatitis B immunoglobulin treatment beyond the immediate perioperative period (the time frame surrounding the surgical procedure). For those receiving extended prophylaxis, the median duration of hepatitis B immunoglobulin treatment was 119 days, with an interquartile range of 10 to 344 days, meaning the middle 50% of patients experienced vastly different treatment timelines. For practicing hepatologists and transplant surgeons, this wide range highlights the heterogeneity in maintenance strategies and underscores the lack of consensus regarding the optimal duration of immunoglobulin therapy in the modern era of potent antiviral medications.

Predictors of Recurrence and Long-Term Survival

The clinical efficacy of the various prophylaxis protocols was measured primarily by the rate of viral relapse. Within the first year following the procedure, a total of 14 patients (5.1%) experienced hepatitis B virus recurrence within 12 months following liver transplantation. To identify the clinical drivers of these relapses, the researchers performed a multivariate analysis, a statistical method used to isolate the independent impact of multiple variables on a single outcome. This analysis indicated that triple immunosuppression following liver transplantation was associated with a significantly increased risk of hepatitis B virus recurrence. In this context, triple immunosuppression refers to the therapeutic use of three distinct classes of medications, typically a calcineurin inhibitor, an antimetabolite, and a corticosteroid, to prevent the immune system from rejecting the donor organ. Long-term patient outcomes remained robust across the study period, regardless of the specific immunoglobulin maintenance strategy employed. The researchers reported that survival rates at 1 year after liver transplantation were 98.2%. This high level of early postoperative success transitioned into stable long-term outcomes, as survival rates at 5 years after liver transplantation were 88.3%. By the end of the follow-up period, the data showed that survival rates at 7 years after liver transplantation were 80.6%. Notably, a Cox regression analysis (a statistical model used to link patient survival times to specific predictor variables) found that only lower intravenous doses of hepatitis B immunoglobulin during the first week post-transplant were associated with 7-year mortality. The risk of recurrence itself did not appear to influence these survival outcomes, suggesting that while intensive immunosuppression may increase the likelihood of viral return, it does not necessarily compromise the long-term viability of the graft or the patient.

Clinical Implications for Maintenance-Free Regimens

The longitudinal data from this study provide a clearer framework for optimizing prophylaxis during the postoperative period. As established by the survival modeling, the researchers identified that only lower intravenous doses of hepatitis B immunoglobulin during the first week after liver transplantation were associated with 7-year mortality. This suggests that while the immediate perioperative window requires robust intravenous dosing to secure long-term survival, the necessity for high-dose or frequent administration diminishes rapidly after the first seven days. This finding isolates the critical period for immunoglobulin efficacy, indicating that clinical focus should be directed toward early stabilization rather than indefinite maintenance. Furthermore, the study results indicate that the intensity of long-term prophylaxis does not need to be tailored to initial risk assessments. The researchers found that hepatitis B immunoglobulin doses after liver transplantation and the risk of hepatitis B virus recurrence groups do not influence clinical outcomes. This lack of association remained consistent regardless of whether patients were initially classified as high risk for viral return. Because the maintenance dose did not significantly impact survival or recurrence rates beyond the first year, the traditional practice of lifelong or extended immunoglobulin therapy appears to offer no additional clinical benefit over nucleos(t)ide analogue monotherapy. Based on these outcomes, the authors conclude that hepatitis B immunoglobulin maintenance-free prophylaxis is a feasible and cost-effective option for most patients. Transitioning to a regimen that relies solely on nucleos(t)ide analogues after the initial post-transplant phase could significantly reduce healthcare expenditures and the logistical burden on patients without compromising the 80.6% survival rate observed at 7 years. For the practicing clinician, these findings support a shift toward more streamlined protocols that prioritize early, adequate intravenous dosing followed by the cessation of immunoglobulin in favor of long-term antiviral suppression.

References

1. Cholongitas E, Papatheodoridis GV. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review.. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2013. doi:10.1111/j.1600-6143.2012.04315.x

2. Katz LH, Paul M, Guy DG, Tur-Kaspa R. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis.. Transplant infectious disease : an official journal of the Transplantation Society. 2010. doi:10.1111/j.1399-3062.2009.00470.x

3. Sheng L, Zhang J, Zhong Z, Sheng X, Ren J, Wang G. High-potency nucleos(t)ide analogues alone or plus immunoglobulin for HBV prophylaxis after liver transplantation: a meta-analysis.. Hepatology international. 2023. doi:10.1007/s12072-022-10466-w

4. Wang P, Tam N, Wang H, et al. Is hepatitis B immunoglobulin necessary in prophylaxis of hepatitis B recurrence after liver transplantation? A meta-analysis.. PloS one. 2014. doi:10.1371/journal.pone.0104480

5. Cholongitas E, Goulis J, Akriviadis E, Papatheodoridis GV. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review.. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2011. doi:10.1002/lt.22354

6. Saab S, Waterman B, Chi AC, Tong MJ. Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review.. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2010. doi:10.1002/lt.21998